Relay Therapeutics Inc. Common Stock vs Teradata Corporation Common Stock — how do they compare? Relay Therapeutics Inc. Common Stock trades at $16.91 (market cap $3.74B), while Teradata Corporation Common Stock trades at $29.6 (market cap $2.78B). The key difference: Relay Therapeutics Inc. Common Stock is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Teradata Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 5 Days and Teradata Corporation Common Stock for 0 Days on average.
| RLAY | TDC | |
|---|---|---|
Market Cap | $3.74B | $2.78B |
Volume | 2,936,788 | 1,442,176 |
Sector | Health | Technology |
52-Week High | $20.75 | $37.88 |
52-Week Low | $6.05 | $20.71 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $2.86B | $2.46B |
Signals from Pluang's Aura AI — not financial advice
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →Teradata Corporation develops a hybrid cloud analytics and data platform, including its Teradata Vantage and VantageCloud products, that helps enterprises manage and analyze data across cloud, on-premises, and hybrid environments. It serves industries including retail, financial services, healthcare, and manufacturing.
Read more on TDC →